Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 199-202 , 15 February 2003

Interferon beta 1a for secondary progressive multiple sclerosis

References 

  1. The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing–remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661
  2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.  Intramuscular interferon beta-1α for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996;39:285–294
  3. PRISMS study group . Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing–remitting multiple sclerosis. Lancet. 1998;353:1498–1504
  4. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology. 1997;49:358–363
  5. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group the University of British Columbia MS/MRI Analysis GroupPRISMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628–1636
  6. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al.  Interferon in relapsing–remitting multiple sclerosis (Cochrane Review). Cochrane Database Syst. Rev. 2001;4:
  7. European Study Group on Interferon β-1b in Secondary Progressive MS . Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–1503
  8. Secondary progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon beta-1a in secondary progressive MS. Clinical Results. Neurology. 2001;56:1496–1504
  9. Goodkin DE  the North American Study Group . Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology. 2000;54:2352
  10. Li D, Zhao GJ, Paty DW  the UBC MS/MRI Analysis Research Group  the SPECTRIMS Study Group . Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results. Neurology. 2001;56:1505–1513
  11. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann. Neurol. 1999;46:850–859
  12. Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, et al.  T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain. 2001;124(Pt. 7):1396–1402
  13. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57:1969–1975
  14. Association of British Neurologists, Guidelines for the use of beta interferons and glatiramer acetate in multiple sclerosis. Association of British Neurologists Report, 1–11 (2001).
  15. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al.  Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178

☆ Paper presented at European Charcot Meeting Venice October 2001.

PII: S0022-510X(02)00334-9

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 199-202 , 15 February 2003

Article Tools

* Image Usage & Resolution